ng28ÄϹ¬

ÌõÄ¿µÄ

FDA×ÉѯίԱ»áÒ»ÖÂͶƱȷÈÏLEQEMBI?£¨lecanemab-irmb£©ÖÎÁư¢¶û´Äº£Ä¬²¡µÄÁÙ´²»ñÒæ

ÖÜΧºÍÖÐÊàÉñ¾­ÏµÍ³Ò©Îï×ÉѯίԱ»á»ùÓÚÔçÆÚ°¢¶û´Äº£Ä¬²¡»¼ÕߵĴóÐÍÈ«ÇòÑéÖ¤ÐÔIIIÆÚClarity ADÁÙ´²ÊÔÑéµÄÊý¾Ý½øÐбí¾ö¡£
×÷ΪÓÅÏÈÉóÆÀ£¬LEQEMBI¹Å°åÉóÅúPDUFAÐж¯ÈÕÆÚÒѶ¨ÔÚ2023Äê7ÔÂ6ÈÕ¡£
LEQEMBIÓÚ2023Äê1ÔÂ6ÈÕÔÚÃÀ¹úʳƷºÍÒ©ÎïÖÎÀí¾Ö¿ìËÙͨµÀÈ϶¨Ï»ñµÃÅú×¼£¬ÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡¡£

ng28ÄϹ¬ÖйúËÕÖݹ¤³§Ë³Àûͨ¹ýÄÜÔ´ÖÎÀíÌåϵÈÏÖ¤

¾­ÖйúÖÊÁ¿ÈÏÖ¤ÖÐÐĵÄÉóºË£¬ng28ÄϹ¬ËÕÖݹ¤³§£¨ÒÔϼò³Æng28ÄϹ¬ÖйúËÕÖݹ¤³§£©Ë³Àûͨ¹ýÁËGB/T23331-2020/ISO50001:2018ÄÜÔ´ÖÎÀíÌåϵÈÏÖ¤²¢È¡µÃÖ¤Ê飬±ê¼Ç×Ång28ÄϹ¬ÖйúËÕÖݹ¤³§ÄÜÔ´ÖÎÀíÌåϵ½¨ÉèÒÔ¼°Éú²ú½ÚÄÜÖÎÀíÔÚ¿ÆÑ§»¯¡¢¾«Ò滯¡¢±ê×¼»¯·½ÃæÈ¡µÃÁËÏÔÖøÐ§¹û¡£

ng28ÄϹ¬½«ÔÚµÚ37½ìÃÀ¹úÁªºÏרҵ˯Ãßѧ»áÉϽéÉÜLemborexantµÄ×îÐÂÊý¾Ý

2023Äê6ÔÂ3ÈÕÖÁ7ÈÕ£¬ng28ÄϹ¬½«ÔÚÃÀ¹úÓ¡µÚ°²Äɲ¨Àû˹¾ÙÐеĵÚ37½ìÃÀ¹úÁªºÏרҵ˯Ãßѧ»á£¨SLEEP 2023£©Äê»áÉÏÐû²¼8·Ý±¨¸æ£¬°üÀ¨ÆäÔ­ÑеÄʳÓûËØÊÜÌåÞ׿¹¼ÁLemborexant£¨²úÆ·Ãû³Æ£ºDAYVIGO?£©µÄ×îÐÂÊý¾Ý¡£

ÀÖÎÀÂê?£¨ÂØ·¥ÌæÄᣩÓë¿ÉÈð´ï?£¨ÅÁ²©ÀûÖéµ¥¿¹£©ÁªÊÊÓÃÒ©×÷ΪÍíÆÚÉöϸ°û°©»¼ÕßµÄÒ»ÏßÖÎÁÆ£¬ÓëÊæÄáÌæÄáÏà±ÈÏÔʾ³öÉú´æÆÚºã¾Ã³¤ÆÚµÄÓÅÊÆ

¾­¹ýËÄÄêµÄËæ·Ã£¬ÔÚÒªº¦ÐÔIIIÆÚCLEAR£¨Ñо¿307£©/KEYNOTE-581ÊÔÑéÖУ¬ÀÖÎÀÂêÁªºÏ¿ÉÈð´ïÓëÊæÄáÌæÄáÏà±È£¬ËÀÍöΣº¦½µµÍ21%¡£
×îÖÕ½á¹û½«ÔÚ2023ÄêµÄASCO¼¯»áÉÏÒÔ¿ÚÍ·ÕªÒªµÄÐÎʽ½øÐÐÐû²¼¡£

ng28ÄϹ¬½«»ý¼«Îª±»ºöÊÓµÄÈÈ´ø²¡ºÍű¼²¿ª·¢ÐÂÒ©£¬²¢ÎªÈ«Çò½¡¿µ¼¼ÊõÕñÐË»ù½ðµÚÈý½×¶ÎÌṩ×ʽðÖ§³Ö

ng28ÄϹ¬ÌåÏÖ£¬½«Ïò¹«ÒæÉçÍÅ·¨ÈËÈ«Çò½¡¿µ¼¼ÊõÕñÐË»ù½ð£¨Global Health Innovative Technology Fund£©ÎªÆÚÎåÄ꣨×Ô2023ÄêÖÁ2027Ä꣩×ܼÆ6.25ÒÚÈÕÔªµÄµÚÈýÆÚ»ù½ð¡£GHIT Fund½¨Á¢ÓÚ2013Äê4Ô£¬ÓɰüÀ¨ng28ÄϹ¬ÔÚÄÚµÄÈÕ±¾ÖÆÒ©ÆóÒµ¡¢ÈÕ±¾¹úÕþ¸®¡¢±È¶ûºÍ÷Áմ¸Ç´Ä²ÆÍŵÈÏàÖúͬ°éÅäºÏÉèÁ¢£¬Ö¼ÔÚÔö½øÈÕ±¾ºÍÍâÑóÑо¿»ú¹¹µÄÏàÖú£¬¼ÓËÙÑз¢Õë¶ÔÉú³¤Öйú¼ÒºÍÐÂÐ˹ú¼ÒµÄѬȾ²¡µÄÁ¢ÒìÒ©Îï¡£ng28ÄϹ¬ÒÑÏòGHIT FundÌṩµÚÒ»ÆÚ£¨2013 – 2017Äê¶È£©ºÍµÚ¶þÆÚ£¨2018 – 2022Äê¶È£©»ù½ð¹²¼Æ10ÒÚÈÕÔªµÄ×ʽðÖ§³Ö¡£

ng28ÄϹ¬½«ÔÚASCO 2023ÉÏÐû²¼×îÐÂÖ×ÁöÑз¢¹ÜÏßÏà¹ØÊý¾ÝºÍ½øÕ¹Çé¿ö

ng28ÄϹ¬Öêʽ»áÉçÐû²¼£¬½«ÔÚ6ÔÂ2ÈÕÖÁ6ÈÕÃÀ¹úÒÁÀûŵÒÁÖÝÖ¥¼Ó¸ç¾ÙÐеÄ2023ÄêÃÀ¹úÁÙ´²Ö×Áöѧ»á£¨ASCO£©Äê»á£¨#ASCO23£©ÉÏ£¬Õ¹Ê¾ÆäÖÖÖÖÐÍÖ×ÁöÑз¢¹ÜÏßµÄÑо¿½øÕ¹Çé¿ö¡£

ng28ÄϹ¬ÔÚÓ¢¹úÌá½»LecanemabÉÏÊÐÐí¿ÉÉêÇë

5ÔÂ22ÈÕ£¬ng28ÄϹ¬ÒÑÏòÓ¢¹úÒ½Ò©ºÍ½¡¿µ²úÆ·ÖÎÀí¾Ö£¨MHRA£©Ìá½»ÁËLecanemabµÄÉÏÊÐÐí¿ÉÉêÇ루MAA£©¡£LecanemabÊÇÒ»ÖÖʵÑéÐÔ¿¹µí·ÛÑùÂѰצ£¨A¦Â£©Ô­ÏËά¿¹Ì壬ÓÃÓÚÖÎÁÆ´óÄÔÖÐÈ·Èϱ£´æµí·ÛÑùÂѰײ¡ÀíµÄÔçÆÚ°¢¶û´Äº£Ä¬²¡£¨AD£©ºÍÇá¶ÈADÒýÆðµÄÈÏÖªÕϰ­¡£LecanemabÒѱ»MHRAÖ¸¶¨ÎªILAP*¡£

ÎÀ¿ËÌ©¿Ú·þ»ìÐüÒº»ñµÃ¹ú¼ÒÒ©Æ·¼à¶½ÖÎÀí¾ÖÅú×¼

ng28ÄϹ¬Ô­Ñп¹ñ²ðïÒ©Îï(ASM) ÎÀ¿ËÌ©?£¨Ó¢ÎÄÃû£ºFycompa?£¬Í¨ÓÃÃû£ºßÁÂØÅÁÄΣ©ÔÚÖйú»ñÅú¿Ú·þ»ìÐüÒº¼ÁÐÍ£¬ÓÃÓÚ³ÉÈ˺Í4Ëê¼°ÒÔÉ϶ùͯñ²ðﲿ·ÖÐÔ±¬·¢»¼Õߣ¨°éÓлò²»°éÓм̷¢È«ÃæÐÔ±¬·¢£©µÄÖÎÁÆ¡£

¼ÓÄôóÎÀÉú²¿½ÓÊÜng28ÄϹ¬ÐÂÒ©LecanemabµÄÉêÇë

5ÔÂ16ÈÕ£¬¼ÓÄôóÎÀÉú²¿ÒѾ­½ÓÊÜÁËLecanemabµÄÐÂÒ©ÉêÇ루NDS£©¡£ LecanemabÊÇÒ»ÖÖʵÑéÐÔ¿¹µí·ÛÑùÂѰצ£¨A¦Â£©Ô­ÏËά*¿¹Ì壬ÓÃÓÚÖÎÁƾßÓÐÄÔ²¿µí·ÛÑùÂѰײ¡ÀíµÄÔçÆÚ°¢¶û´Äº£Ä¬²¡£¨AD£©¡ª¡ª°üÀ¨ÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­ºÍÇá¶ÈAD¡£

ng28ÄϹ¬Öйú×ܲ÷ëÑÞ»ÔÒ»Ðлá¼û¹ú¿ØºÓÄÏ

5ÔÂ11ÈÕÉÏÎ磬ng28ÄϹ¬Öйú×ܲ÷ëÑÞ»ÔݰÁÙ¹ú¿ØºÓÄϵ÷ÑÐÖ¸µ¼ÊÂÇ飬ng28ÄϹ¬Öйú¸±×ܲÃÀîÔÆÁú¡¢ng28ÄϹ¬Öйú±±Öйú×¼È벿²¿³¤ÕÔ½¨¾ý¡¢ng28ÄϹ¬Öйú×¼ÈëÖÎÀí±¾²¿ÖÐÇø´óÇø¾­ÀíÏÄÈðÓ¢µÈÅãͬ¡£¹úÒ©¿Ø¹É¸±×ܲᢹú¿ØºÓÄ϶­Ê³¤³ÂÕ½Óî¡¢¹ú¿ØºÓÄÏ×ܾ­ÀíÕÅÕÙ»Ô¡¢¹úÒ©¿Ø¹ÉÈ«²ÉÖÐÐĸ±×ܾ­ÀíÐ캣¡¢¹ú¿ØºÓÄÏ×ܾ­ÀíÖúÀíÀî½Ü£¬¹úÒ©¿Ø¹É¹©Ó¦Á´ÒµÎñÉú³¤²¿²¿³¤Ñî·«µÈ½Ó´ýÁË·ëÑÞ»ÔÒ»ÐС£

ÍøÕ¾µØÍ¼